These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22718922)

  • 1. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
    Pavelka K; Kavanaugh AF; Rubbert-Roth A; Ferraccioli G
    Rheumatology (Oxford); 2012 Jul; 51 Suppl 5():v12-21. PubMed ID: 22718922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):283-8. PubMed ID: 21595176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO
    Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
    Brezinschek HP; Brickmann K; Yazdani-Biuki B; Dörner T; Graninger WB; Brezinschek RI
    Wien Med Wochenschr; 2006 Jan; 156(1-2):61-7. PubMed ID: 16465615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis.
    Desai RJ; Hansen RA; Rao JK; Wilkins TM; Harden EA; Yuen A; Jonas DE; Roubey R; Jonas B; Gartlehner G; Lux L; Donahue KE
    Ann Pharmacother; 2012 Nov; 46(11):1491-505. PubMed ID: 23092868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.
    Callhoff J; Weiß A; Zink A; Listing J
    Rheumatology (Oxford); 2013 Dec; 52(12):2127-35. PubMed ID: 23946435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmet needs in rheumatoid arthritis.
    Moreland L
    Arthritis Res Ther; 2005; 7 Suppl 3(Suppl 3):S2-8. PubMed ID: 15960819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of biologic therapies in the treatment of rheumatoid arthritis.
    Wang D; Li Y; Liu Y; Shi G
    Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Painful rheumatoid arthritis.
    Smith HS; Smith AR; Seidner P
    Pain Physician; 2011; 14(5):E427-58. PubMed ID: 21927056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.
    Mandema JW; Salinger DH; Baumgartner SW; Gibbs MA
    Clin Pharmacol Ther; 2011 Dec; 90(6):828-35. PubMed ID: 22048227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.